Form 4: Guardant Health CCO Reports Routine Stock Transactions

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Summary

• Chris Freeman, Chief Commercial Officer of Guardant Health, Inc. (GH), reported transactions involving company common stock.
• On September 15, 2025, 1,402 shares of common stock were acquired upon the vesting of restricted stock units (RSUs).
• Concurrently, 594 shares were disposed of at a price of $54.79 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Freeman beneficially owns 49,629 shares of common stock directly.
• Additionally, 4,206 restricted stock units remain beneficially owned, which are part of an award granted on June 9, 2023, with a vesting schedule extending over the next two years.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (RSU vesting and tax withholding) which are neutral in sentiment, reflecting standard executive compensation practices without indicating any significant positive or negative operational or financial developments for the company.

Positives

• The vesting of restricted stock units indicates continued equity participation and alignment of management interests with shareholders.
• The acquisition of 1,402 shares of common stock through RSU vesting increases the direct beneficial ownership of the Chief Commercial Officer.

Negatives

• A disposition of 594 shares occurred to cover tax withholding obligations, resulting in a reduction of direct share ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor impact as these are routine, pre-scheduled compensation-related transactions by an executive, not indicative of discretionary selling or buying based on new material information.

Next Steps

• Remaining 67% of the restricted stock unit award will vest in equal quarterly installments over the next two-year period.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax withholding). It does not provide new material information about Guardant Health's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, suggesting no new fundamental reason to alter an existing position based solely on this filing.

Keywords

Guardant Health, GH, Chris Freeman, Chief Commercial Officer, Insider Transaction, Form 4, Restricted Stock Units, RSU vesting, Stock ownership, Tax withholding